Leading breast cancer therapy, Herceptin keeps exclusivity by next year
In the domestic breast cancer treatment market, the Roche’s influence is expected to be kept, at least, by 2017.
This is because Celltrion which acquire approval of the Herceptin’s biosimilar, ‘Herzuma,’ has recently failed in the nullification trial of the Herceptin’s composition patent.
Accor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
